System Biological Analyses of Innate and Adaptive Responses to Vaccination
对疫苗接种的先天和适应性反应的系统生物学分析
基本信息
- 批准号:10056675
- 负责人:
- 金额:$ 240.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAffectAgonistAntibody ResponseAntigensAttenuatedAutomobile DrivingB-LymphocytesBiologicalCD4 Positive T LymphocytesCellsClinicalClinical TrialsCollaborationsDataData SetDevelopmentElderlyGene Expression ProfilingGlycoproteinsGoalsHerpes zoster diseaseHerpesvirus Type 3HumanImmune responseImmunityImmunologicsInnate Immune ResponseInvestigationLiposomesMalaria VaccinesMemoryMemory B-LymphocyteMolecularNamesNatural ImmunityPathway interactionsPeripheral Blood Mononuclear CellPlasmablastPopulationPublic HealthQS21RecombinantsResearchResearch PersonnelResolutionSaponinsSerumSubunit VaccinesSystemSystems AnalysisSystems BiologyT cell responseT-LymphocyteTLR4 geneTechnologyVaccinationVaccinesVirusWorkZoster Vaccineadaptive immune responseage groupbasebiological systemscytokinedata managementhuman very old age (85+)insightmetabolomicsnovel vaccinesresponsesingle cell technologyvaccine efficacy
项目摘要
The research proposed in years 6 and 7 of the Emory-HIPC will build on the considerable progress made
during the first 5 years in using systems based approaches to understand the molecular networks driving
innate and adaptive immune responses to vaccination. The major focus of the work planned in years 6
and 7 is to understand the immunological mechanisms by which the recently licensed subunit vaccine for
herpes zoster (HZ, shingles) induces highly efficacious protection against shingles. HZ which is caused by
the varicella zoster virus (VZV), affects several million people/year globally, and is a significant public
health concern for the elderly. An important recent development is the development of a new subunit HZ
vaccine, which contains the recombinant glycoprotein E subunit (“gE vaccine”), adjuvanted with AS01, a
liposome-based adjuvant system containing the TLR4 agonist MPL, and the saponin, QS21 (1-4). The gE
vaccine has recently been licensed for clinical use in subjects older than 50 years, under the trade name
Shingrix®. Remarkably, the efficacy of Shingrix® is high (91%) even in 70 year old vaccinees (1-4).
Although Shingrix® has revealed superior antibody responses and greater durability of CD4+ T cell
responses to the gE vaccine, a comprehensive assessment of immune responses to the gE vaccine is
lacking. This will be achieved in Aims 1 and 2, where we will analyze the innate and adaptive responses
to Shingrix®. Importantly we will analyze these results in the context of data generated from our previous
HIPC project on immune responses induced by the live attenuated zoster vaccine, Zostavax®.
Aim 1: Systems analysis of innate responses elicited by Shingrix® in 50-60 year old and >70 year old
subjects.
Aim 2: To analyze the adaptive immune response elicited by Shingrix® in 50-59 year old and >70-85
years old subjects.
埃默里-重债穷国倡议第6年和第7年拟议的研究将以已取得的重大进展为基础
在使用基于系统的方法来理解分子网络驱动的前5年中,
对疫苗接种的先天性和适应性免疫应答。未来几年计划的工作重点6
和7是了解最近批准的亚单位疫苗的免疫机制,
带状疱疹(HZ,带状疱疹)诱导针对带状疱疹的高效保护。HZ由以下因素引起
水痘带状疱疹病毒(VZV)每年影响全球数百万人,是一种重要的公共病毒,
关注老年人的健康。一个重要的最近发展是一个新的亚基HZ的发展
疫苗,其含有重组糖蛋白E亚单位(“gE疫苗”),用AS 01作为佐剂,
含有TLR 4激动剂MPL和皂苷QS 21的基于脂质体的佐剂系统(1-4)。的gE
疫苗最近被许可用于50岁以上的受试者的临床使用,商品名为
Shingrix®。值得注意的是,即使在70岁的接种者(1-4岁)中,Shingrix®的有效性也很高(91%)。
尽管Shingrix®已经显示出上级抗体应答和更大的CD 4 + T细胞耐受性,
gE疫苗免疫应答的综合评估,
缺乏这将在目标1和目标2中实现,我们将分析先天和适应性反应,
到Shingrix®。重要的是,我们将分析这些结果的背景下产生的数据,从我们以前的
关于带状疱疹减毒活疫苗Zostavax®诱导的免疫应答的HIPC项目。
目的1:系统分析Shingrix®在50-60岁和>70岁人群中引发的先天反应
科目
目的2:分析Shingrix®在50-59岁和>70-85岁人群中引发的适应性免疫应答
岁的科目。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rafi Ahmed其他文献
Rafi Ahmed的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rafi Ahmed', 18)}}的其他基金
System Biological Analyses of Innate and Adaptive Responses to Vaccination
对疫苗接种的先天和适应性反应的系统生物学分析
- 批准号:
10345981 - 财政年份:2021
- 资助金额:
$ 240.49万 - 项目类别:
System Biological Analyses of Innate and Adaptive Responses to Vaccination
对疫苗接种的先天和适应性反应的系统生物学分析
- 批准号:
10375723 - 财政年份:2021
- 资助金额:
$ 240.49万 - 项目类别:
System Biological Analyses of Adaptive Responses to vaccination
疫苗接种适应性反应的系统生物学分析
- 批准号:
10201503 - 财政年份:2020
- 资助金额:
$ 240.49万 - 项目类别:
Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy
利用 PD-1 的力学生物学进行癌症免疫治疗
- 批准号:
10174887 - 财政年份:2020
- 资助金额:
$ 240.49万 - 项目类别:
Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy
利用 PD-1 的力学生物学进行癌症免疫治疗
- 批准号:
10408747 - 财政年份:2020
- 资助金额:
$ 240.49万 - 项目类别:
Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy
利用 PD-1 的力学生物学进行癌症免疫治疗
- 批准号:
10524207 - 财政年份:2020
- 资助金额:
$ 240.49万 - 项目类别:
System Biological Analyses of Innate and Adaptive Responses to Vaccination
对疫苗接种的先天和适应性反应的系统生物学分析
- 批准号:
10201491 - 财政年份:2020
- 资助金额:
$ 240.49万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 240.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 240.49万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 240.49万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 240.49万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 240.49万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 240.49万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 240.49万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 240.49万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 240.49万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 240.49万 - 项目类别: